| Mr Brett Guy Flowers, RPH | |
|
1 Pinckney Blvd, Beaufort, SC 29902-6122 | |
| (843) 228-6411 | |
| Not Available |
| Full Name | Mr Brett Guy Flowers |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1 Pinckney Blvd, Beaufort, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790830362 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 015501 (Georgia) | Secondary |
| 183500000X | Pharmacist | PS0023090 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Brett Guy Flowers, RPH 1 Pinckney Blvd, Beaufort, SC 29902-6122 Ph: (843) 228-5411 | Mr Brett Guy Flowers, RPH 1 Pinckney Blvd, Beaufort, SC 29902-6122 Ph: (843) 228-6411 |
News Archive
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
Exercise training is safe in heart failure patients, does not significantly reduce hospitalization or death, but is associated with several improved clinical outcomes, even in those already receiving optimal medical care, researchers reported at the American Heart Association's Scientific Sessions 2008. The Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) was presented as a late-breaking clinical trial.
Swedish researchers report that overall adherence to treatment guidelines for acute otitis media in children is good, at 70–90%, but that adherence to watchful waiting is poor.
ConvaTec, a world-leading provider of medical technologies for community and hospital care, today announced that it has made an initial donation of more than $400,000 in medical supplies to rescue and relief efforts in Haiti, following the devastating earthquake that hit that nation last week.
AbbVie, a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.
› Verified 4 days ago
Andrew Francis Dylewski, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 155 Sea Island Pkwy, Beaufort, SC 29907 Phone: 843-522-6819 Fax: 843-522-9317 | |
Justin Ford, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2363 Boundary St, Beaufort, SC 29902 Phone: 843-322-0308 | |
Frannie Farmer, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1294 Ribaut Rd, Beaufort, SC 29902 Phone: 843-522-8503 Fax: 843-522-3685 | |
Dr. Lashawn Johnson Cromwell, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 350 Robert Smalls Pkwy, Beaufort, SC 29906 Phone: 843-522-8687 Fax: 843-522-8987 | |
Dr. Jeremy Michael Simmons, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 968 Ribaut Rd Ste 1, Beaufort, SC 29902 Phone: 843-379-3278 Fax: 843-379-3232 | |
Jesse Blalock, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 350 Robert Smalls Pkwy, Beaufort, SC 29906 Phone: 843-522-8687 | |
Patrick Spado, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 136 Sea Island Pkwy, Beaufort, SC 29907 Phone: 843-522-0707 Fax: 843-522-2733 |